PN patients with elevated CCL2, CCL7, and CCL13 but not CCL8 expression had a shorter survival time compared to the low expressers for each of the genes, while in contrast to PN, expression levels of MCPs did not correlate with the survival of the patients with MES signature GBM. The gene discussed is CCL2; the disease is glioblastoma.